» Articles » PMID: 35208539

Comparative Study of Early Impacts of Post-COVID-19 Pneumonia on Clinical Manifestations, Pulmonary Function, and Chest Radiographs

Abstract

: Scant data regarding early post-COVID-19 effects are available, especially in younger people. Therefore, the objective of this study was to explore the early clinical impacts of post-COVID-19 pneumonia, comparing severe and non-severe patients. : A cross-sectional study was conducted in adult patients admitted with COVID-19 pneumonia from April to May 2021. Demographic data, symptoms and signs, quality of life, Hospital Anxiety and Depression Scale (HADS), chest radiograph (CXR), pulmonary function tests (spirometry, impulse oscillometry), fractional exhaled nitric oxide (FeNO), and exercise capacity were assessed one month after hospital discharge. Twenty-five healthy control subjects that were age- and gender-matched were recruited for comparisons. : One hundred and five patients, with a mean age of 35.6 ± 15.8 years and 54 (51.4%) males, participated and were categorized into the non-severe pneumonia (N = 68) and severe pneumonia groups (N = 37). At a one-month follow-up visit (the time from the onset of the disease symptoms = 45.4 ± 5.9 days), the severe group had more cough, fatigue, and skin rash with higher dyspnea scale, more residual CXR lesions, and lower quality of life scores. Forced vital capacity (FVC) was lower in the severe group (88.3% of predicted value) and non-severe group (94.6% of predicted value) than in the healthy controls ( = 0.001). The six-minute walk distance was significantly lower in the non-severe group, at 79.2 m, and in the severe group, at 103.8 m, than in the healthy control subjects ( < 0.001). : Adult patients with COVID-19, especially those with clinically severe pneumonia, still had residual symptoms and chest radiographic abnormalities, together with poorer quality of life and lower exercise capacity, one month after hospital discharge.

Citing Articles

Prevalence of skin manifestations in patients with COVID-19: a systematic review and meta-analysis.

de Aguiar B, Ferreira E, De Luca Canto G, Guerra E, Reis P Front Med (Lausanne). 2024; 11:1390775.

PMID: 39234048 PMC: 11371801. DOI: 10.3389/fmed.2024.1390775.


The long-term impact of COVID-19 pneumonia on pulmonary function and exercise capacity.

Chaiwong W, Deesomchok A, Pothirat C, Liwsrisakun C, Duangjit P, Bumroongkit C J Thorac Dis. 2023; 15(9):4725-4735.

PMID: 37868845 PMC: 10586982. DOI: 10.21037/jtd-23-514.


Radiological and Functional Pulmonary Evolution in Post-COVID-19 Patients: An Observational Study.

Maria Cavallari Strozze Catharin V, Zutin T, Landgraf Guiguer E, Cressoni Araujo A, Fornari Laurindo L, Chagas E Diseases. 2023; 11(3).

PMID: 37754309 PMC: 10528437. DOI: 10.3390/diseases11030113.


Risk of long COVID main symptoms after SARS-CoV-2 infection: a systematic review and meta-analysis.

Marjenberg Z, Leng S, Tascini C, Garg M, Misso K, El Guerche Seblain C Sci Rep. 2023; 13(1):15332.

PMID: 37714919 PMC: 10504382. DOI: 10.1038/s41598-023-42321-9.


Long-Term Impacts of COVID-19 Pneumonia on Quality of Life: A Single Institutional Pilot Study.

Deesomchok A, Liwsrisakun C, Chaiwong W, Pothirat C, Duangjit P, Bumroongkit C Healthcare (Basel). 2023; 11(13).

PMID: 37444797 PMC: 10341595. DOI: 10.3390/healthcare11131963.


References
1.
Chen W, Zheng K, Liu S, Yan Z, Xu C, Qiao Z . Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbiol Antimicrob. 2020; 19(1):18. PMC: 7227180. DOI: 10.1186/s12941-020-00362-2. View

2.
Todt B, Szlejf C, Duim E, Linhares A, Kogiso D, Varela G . Clinical outcomes and quality of life of COVID-19 survivors: A follow-up of 3 months post hospital discharge. Respir Med. 2021; 184:106453. PMC: 8116128. DOI: 10.1016/j.rmed.2021.106453. View

3.
Demirci N, Ugras Dikmen A, Tasci C, Dogan D, Arslan Y, Ocal N . Relationship between chest computed tomography findings and clinical conditions of coronavirus disease (COVID-19): A multicentre experience. Int J Clin Pract. 2021; 75(9):e14459. DOI: 10.1111/ijcp.14459. View

4.
. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005; 171(8):912-30. DOI: 10.1164/rccm.200406-710ST. View

5.
Devlin N, Krabbe P . The development of new research methods for the valuation of EQ-5D-5L. Eur J Health Econ. 2013; 14 Suppl 1:S1-3. PMC: 3728454. DOI: 10.1007/s10198-013-0502-3. View